Because of the clinical importance of papillomavirus infections, and the risk of malignant progression of some of the lesions induced by this group of viruses (zur Hausen, 1991) , the study of their transformation potential and characteristics acquires particular importance. Although in recent years experimental systems have been developed which allow investigation into in vitro cell transformation by human papillomaviruses (HPVs), the first steps in the molecular aspects of cell transformation were made with animal papillomaviruses, first and foremost bovine papillomavirus type l (BPV-1). In addition animal systems have highlighted the interaction between virus and cofactors in oncogenesis, and have the unique advantage over the human one that direct experimentation is feasible. Thus, BPV-4-associated carcinogenesis of the alimentary canal of cattle (Jarrett et al., 1978) has been experimentally reproduced both in cattle (Campo & Jarrett, 1987) and in mice (Gaukroger et al., 1991) . Furthermore, Ito & Evans (1961) showed that naked DNA of cottontail rabbit papillomavirus (CRPV) was infectious and oncogenic, thus leading to the detailed investigation of CRPV-associated tumorigenesis in several laboratories (Nasseri & Wettstein, 1987; Brandsma et al., 1991) .
In this brief review, which is not intended to be comprehensive of all the work done on animal papillomaviruses, I shall focus on three animal models: cattle, rabbit and monkey, and their respective viruses. A comparison of the transformation characteristics of these viruses within this group and with the human viruses will show that the same end product, cell transformation, can be achieved by employing different strategies.
Different papillomaviruses have different cell transformation potentials (Table 1) . Some viruses can fully transform primary cells with no need for additional oncogenes; these viruses are chiefly the fibropapillomaviruses, such as BPV-1 and -2 (Morgan & Meinke, 1980; Jarrett, 1985) . Other viruses, such as the high-risk genital HPVs, of which only HPV-16 will be discussed here, and rhesus monkey papillomavirus (RhPV), can fully transform primary rodent kidney cells only in cooperation Activated ras required for partial transformation of primary bovine fibroblasts. Two-step transformation of sflEp cells.
with another oncogene, typically activated ras (Matlashewski et al., 1987; Schneider et al., 1991) . Primary human cervical keratinocytes are fully transformed by HPV-16 and ras (DiPaolo et al., 1989) , whereas in the same conditions primary human fibroblasts are only partially transformed (Matlashewski et al., 1988) . However, HPV-16 can immortalize murine and human primary keratinocytes and fibroblasts with no requirement for another oncogene (Pirisi et al., 1987; Matlashewski et al., 1988) . These immortalized cells are not tumorigenic in vivo, and are therefore considered premalignant. More information about the immortalizing and transforming capability of HPV-16 can be obtained in a recent review by DiMaio !~.!,991). BPV-4 cannot immortalize primary bovine fibroblasts by itself, and requires the presence of activated ras to transform them partially; these cells are not tumorigenic (Jaggar et al., 1990) . The low immortalization/transformation potential of BPV-4 may be due to the lack of one of the viral oncogenes (see below). CRPV does not require additional oncogenes for transformation of sflEp rabbit keratinocytes, but the transformation process goes through two clearly defined steps: increased growth potential and morphological transformation proper (Meyers & Wettstein, 1991) .
RhPV is the best qualified as a model for human 0001-0629 © 1992 SGM (1990) , it infects the genital tract, its presence is associated with various degrees of dysplasia and neoplasia, its in vitro transformation characteristics are very similar to those of HPV-16 (Schneider et al., 1991) , and the two genomes are very close in evolutionary terms . It is interesting that a papillomavirus isolated from skin lesions of a colobus monkey is related to the human cutaneous viruses HPV-5 and -8 (Kloster et al., 1988) , and a papillomavirus isolated from the papillary lesions of the oral cavity of pigmy chimpanzees is related to HPV-13 (Van Ranst et al., 1991) , the agent of oral focal epithelial hyperplasia in humans (Pfister et al., 1983) , suggesting a close relationship between anatomical site and virus type in monkeys and in humans. Resza et al. (1991) have isolated a second papillomavirus from colobus monkeys, which transforms established cells with the same frequency as BPV-1; it is not known whether this virus can transform primary cells. In all papillomaviruses, the early region of the viral genome is responsible for transformation; however, recently it has become clear that the late region too can play a significant role. The whole late region of BPV-1 can be deleted without appreciable loss of transformation efficiency, at least in established cells (Lowy et al., 1980; Campo & Spandidos, 1983) , whereas Meyers & Wettstein (1991) have shown that the CRPV genome possesses an element within the 3' end of the L1 open reading frame (ORF) which is required for transformation of rabbit keratinocytes; another element within the 5' end of the L2 ORF inhibits NIH 3T3 transformation (Table 2) .
Perhaps the most peculiar in its transformation behaviour is BPV-4; its genome is required for induction of the transformed state both in vivo and in vitro, but is not present either in frank cancers or in fully transformed cells, indicating that additional events play an important role in progression and maintenance of the neoplastic state (Campo et al., 1985; Smith & Campo, 1989) (Table  3) . Accordingly, in naturally occurrring cancers the cellular ras gene is activated and occasionally amplified (Campo et al., 1990) That the loss of BPV-4 DNA in transformed cells is not an in vitro artefact has been proved in the nude mouse xenograft system, a technique pioneered by Kreider et al. (1986) . We have recently reported the spontaneous malignant progression of one of 57 BPV-4-induced papillomatous cysts in the nude mouse renal capsule (Gaukroger et al., 1991) . Viral DNA was detected only in the papilloma fronds but not in the cancer and metastases, in agreement with our previous findings (Campo et al., 1985) . We are expanding this work, to mimic the cooperation between BPV-4 and chemical carcinogens as observed in the field. Treatment of the nude mice with either the tumour promoter 12-0-tetradecanoylphorbol-13-acetate or the initiator dimethylbenzanthracene dramatically increased the progression rate, with six of 12 and 14 of 20 cases respectively progressing to malignancy. Again no viral DNA was found in those cancers tested (J. Gaukroger et al., unpublished results). These results confirm the synergism between viral and chemical carcinogens, and suggest that BPV-4 can cooperate with either an initiator or a promoter substance. We are currently investigating in the same experimental system the synergism between BPV-4 and quercetin, a mutagen present in bracken fern which may be the environmental co-carcinogen in oncogenesis in cattle (Jarrett et al., 1978; Campo & Jarrett, 1987) . As a rule, papillomaviruses have two oncogenes which can cooperate in transformation (Table 4) . Thus the oncogenes of BPV-1 are E5 and E6 (Schiller et al., 1984 (Schiller et al., , 1986 Yang et al., 1985; Schlegel et al., 1986) ; of HPV-16, E6 and E7 (Munger et al., 1989 a; Watanabe et al., 1989) ; and of BPV-4, E7 and possibly E8 (Jaggar et al., 1990; Jackson et al., 1991) . E6 is the major transforming gene of CRPV in in vitro assays in which E7 contributes less (Meyers & Wettstein, 1991) , but E7 is essential for tumour formation in vivo (Brandsma et al., 1991) , thus providing functions that E6 lacks. Conversely the only oncogene of HPV-8 seems to be E6 (Iftner et al., 1990) .
Several domains have been identified in HPV-16 E7 by various laboratories (Dyson et al., 1989; Munger et al., 1989b; Barbosa et al., 1990) : the p105 retinoblastoma gene product (Rb)-binding domain, the casein kinase II (CKII) phosphorylation sites, and the two zinc-binding Cys-x-x-Cys motifs (Table 5 ). The transformation properties of HPV-16 E7 depend primarily on Rb-binding and zinc-binding; mutations in either of these two domains abolish transformation (Edmonds & Vousden, 1989; Chesters et al., 1990) , highlighting their critical role. Binding of E7 to p 105Rb prevents the interaction of the latter with its natural targets (Defeo-Jones et al., 1991; Rustgi et al., 1991) ; the zinc fingers are essential for the trans-activation activity of E7 (Phelps et al., 1988) and mutations that disrupt them destabilize the protein (Storey et al., 1990) . The CKII sites, although less critical (Watanabe et al., 1990; Storey et al., 1990) , nevertheless contribute to the transforming activity of HPV-16 E7 (Barbosa et al., 1990; Firzlaff et al., 1991) . BPV-4 E7 does not have serine residues at positions 31 and 32, which are phosphorylated in HPV-16 E7, but has the necessary p l05Rb-binding domains (Jaggar et al., 1990; Jackson et al., 1991) . Given that continued expression of BPV-4 is not necessary for the maintenance of the transformed state (Campo et al., 1985; Jaggar et al., 1990) , it is reasonable to postulate that either binding of pl05Rb by BPV-4 ET, albeit transient, is crucial or the protein has yet another function. The E7 proteins of BPV-1 and HPV-8 do not have either the Rb-binding site or the CKII site (Iftner et al., 1990) and are not transforming (Iftner et al., 1988) . Instead they are involved in the regulation of DNA copy number, as shown by Lusky & Botchan (1985) and Iftner et al. (1988) , respectively. CRPV E7 also lacks the CKII domain (Barbosa & Wettstein, 1988) but, as stated above, is nonetheless necessary for full malignant transformation in vivo (Brandsma et al., 1991) .
E6 is the second major oncogene of both BPV-1 and HPV-16 (Schiller et al., 1984; Yang et al., 1985; Munger et al., 1989a; Watanabe et al., 1989) . Like E7, E6 binds zinc through Cys-x-x-Cys repeats (Barbosa et al., 1989) . BPV-1 E6 is a probable transcriptional activator (Lamberti et al., 1990) , which may contribute to cell transformation by altering the transcriptional programme of critical cellular genes. In addition to being a potential transcriptional activator (Lamberti et al., 1990; Sedman et al., 1991) , HPV-16 E6 binds another negative regulator of the celt cycle, p53, promoting its degradation through the ubiquitin pathway Scheffner et al., 1990) , and therefore sequestering it from controlling cell proliferation.
The E6 ORF is present in all the papillomaviruses sequenced so far, with the notable exception of the epithelial BPVs (Table 6) (Jackson et al., 1991) . These viruses all lack an E6 ORF. They are low in sequence similarity over the area where the E6 ORF ought to be, while displaying a high degree of relatedness throughout the rest of their genomes.
In these BPVs, further 5' to the E7 ORF, there is the small E8 ORF which encodes a peptide very similar to E5, the major oncoprotein of BPV-1. The E8 peptide is highly hydrophobic and theoretically capable of forming a transmembrane a-helix, similar to the one postulated for E5 (Fig. 1) . However, critical amino acids, which have been shown to be necessary for transformation (Horwitz et al., 1988 (Horwitz et al., , 1989 , are either missing, such as the two terminal Cys residues, or are different in E8. Moreover, E5 transforms cells in vitro (Schiller et al., 1986 ) but E8 does not, and its overexpression in the absence of other BPV-4 genes is lethal (Jaggar et al., 1990 et al., 1989) ; BPV-4 E8 has been similarly oriented, although its configuration remains to be proved. The amino acids of BPV-1 E5 that have been shown to be critical for cell transformation (Horwitz et al., 1988 (Horwitz et al., , 1989 are shaded.
expression assays, it is found mostly localized in membranes and the Golgi apparatus and to a lesser degree in the plasma membrane (W. D. Pennie & M. S. Campo, unpublished results), similar to BPV-1 E5 (Burkhardt et al., 1989) . BPV-1 E5 has been shown to activate EGF, PDGF and other membrane receptors (Martin et al., 1989; Petti et al., 1991) , and to bind a 16K cellular protein (Goldstein & Schlegel, 1990) , recently identified as the 16K component of gap junctions and of the vacuolar proton channel-forming ATPase (Goldstein et al., 1991) , involved both in cell-cell communication and in intracellular traffic (Leitch & Finbow, 1990; Finbow et al., 1991) . The activation of several membrane receptors by E5 can be ascribed, at least in part, to the E5-16K complex: the resulting malfunction or disruption of the 16K functions involved in acidification of endosomal vesicles would lead to prolonged ligand-receptor interactions, receptor activation and cell transformation (Goldstein et al., 1991; Finbow et al., 1991) . Alternatively, or in addition, E5 may bind the gap junctional form of 16K, interfering with cell-cell communication and releasing the cell expressing E5 from the control exerted by neighbouring normal cells, thus contributing to cell transformation. Both BPV-1-and BPV-4-transformed cells lack junctional communication (W. D. Pennie, J. Pitts & M. S. Campo, unpublished results) and we ascribe this effect to the binding of E5 and E8 respectively to 16K, although this awaits formal experimental proof.
Recently attention has been focused on the activity of the E 5 0 R F of several HPVs. Since Chen & Mounts (1990) showed that E5 of HPV-6 can transform established cells, a search for a common mechanism of transformation by the different E5 proteins has revealed that HPV-16 E5, like BPV-1 E5, can activate EGF receptors (Pim et al., 1992) It is clear that, despite their similar genetic plan and overall homology, papillomaviruses use different strategies to achieve their common goals. Continuous viral gene expression appears to be mandatory for the maintenance of the neoplastic state in some cases, but not in others; the same protein can have two different roles in two different viruses, or be absent in a third, and it is not inconceivable that a protein may have two different functions in two different cell types, although this has yet to be established.
The results obtained in animal systems have paved the way for research on HPVs and the part they play in cell transformation. Some questions, such as the role of the immune system in virus control and tumour regression, and the usefulness of antiviral or anti-tumour vaccines, can only be addressed in animal systems. Only in animals can the immune response be studied following experimental infection and vaccination of the natural host (Jarrett et al., 1991; Christensen et al., 1991) . 
